Esperion Therapeutics, Inc.
NASDAQ:ESPRBiotechnology
+$0.00 today
- Market cap
- $661.15M
- Beta
- 1.07
- P/E (TTM)
- -107.3
- EPS (TTM)
- -$0.03
Volume 0.00M
Average 12.29M
ESPR Net Income
Bottom-line profit after all expenses, interest, and taxes.
Esperion Therapeutics, Inc.NASDAQ: ESPR
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$25.2M, compared with -$40.46M a year earlier. Trailing-twelve-month net income was -$7.42M.
Context
- Net income amounted to 5.6% of revenue in FY2025, down 9.9 pp from a year earlier.
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$8.06M (+64.5%) for the fiscal year ending Dec 2026, a step up from the +56.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$25.2M-140.7% QoQ
- Last fiscal yearDec 2025
- -$22.68M+56.2% YoY
- LTMMar 2026
- -$7.42M+95.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +37.7% | +97.2% | +59.5 pp |
| 1 year | +56.2% | +64.5% | +8.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (22.68M) USD
- Year-over-year change
- +56.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (22.68M) | +56.2% |
| FY2024 | 2024-12-31 | (51.75M) | +75.3% |
| FY2023 | 2023-12-31 | (209.25M) | +10.4% |
| FY2022 | 2022-12-31 | (233.66M) | +13.2% |
| FY2021 | 2021-12-31 | (269.11M) | — |
Net Income vs competitors
How ESPR compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +95.2% is the highest of 10, against a peer median of -10.2%.
- Net income amounts to 1.8% of revenue for ESPR, versus a peer median of 21.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $20.26M USD | -58.2% | -11.8% | 21.6% | |
| LTM Mar 2026 | -$7.42M USD | +95.2% | — | 1.8% | |
| LTM Mar 2026 | -$8.6M USD | +93.5% | — | 1.3% | |
| LTM Mar 2026 | -CA$10.98M CAD | +89.7% | — | 1.2% | |
| LTM Mar 2026 | -$44.17M USD | -6.7% | — | — | |
| LTM Mar 2026 | -$60.01M USD | +58.1% | — | 7.3% | |
| LTM Mar 2026 | -$68.91M USD | -27.1% | — | 137.1% | |
| LTM Mar 2026 | -$118.44M USD | -10.2% | — | 6450.8% | |
| LTM Mar 2026 | -$185.15M USD | -43.6% | — | — | |
| LTM Mar 2026 | -$290.01M USD | -83.9% | — | 330.2% | |
| Peer median (excluding ESPR) | — | -10.2% | -11.8% | 21.6% | |
Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 78.45M | 75.48M | 116.33M | 332.31M | 403.14M |
| Cost of Revenue | 14.22M | 26.97M | 43.27M | 68.6M | 129.22M |
| Gross Profit | 64.23M | 48.51M | 73.07M | 263.71M | 273.91M |
| Gross Margin | 81.9% | 64.3% | 62.8% | 79.4% | 67.9% |
| Research & Development | 105.98M | 118.93M | 86.11M | 46.24M | 47.85M |
| Selling, General & Admin | 184.99M | 109.08M | 142.52M | 163.07M | 165.79M |
| Operating Expenses | 290.96M | 228.01M | 228.63M | 209.31M | 213.64M |
| Depreciation & Amortization | 612K | 500K | 164K | 63K | 105K |
| EBITDA | (222.14M) | (176.35M) | (150.11M) | 7.57M | 63.87M |
| EBITDA Margin | -283.2% | -233.7% | -129.0% | 2.3% | 15.8% |
| Operating Income | (226.73M) | (179.5M) | (155.56M) | 54.4M | 60.27M |
| Operating Margin | -289.0% | -237.8% | -133.7% | 16.4% | 15.0% |
| Interest Income | 0 | 0 | 0 | 0 | 3.5M |
| Interest Expense | 46.35M | 56.81M | 58.98M | 59.25M | 84.6M |
| Other Income / Expenses | (42.38M) | (54.16M) | (53.69M) | (106.15M) | (81.11M) |
| Income Before Tax | (269.11M) | (233.66M) | (209.25M) | (51.75M) | (20.84M) |
| Pre-Tax Margin | -343.0% | -309.6% | -179.9% | -15.6% | -5.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.84M |
| Net Income | (269.11M) | (233.66M) | (209.25M) | (51.75M) | (22.68M) |
| Net Margin | -343.0% | -309.6% | -179.9% | -15.6% | -5.6% |
| EPS (Basic) | (11.03) | (4.33) | (2.03) | (0.28) | (0.11) |
| EPS (Diluted) | (11.03) | (4.33) | (2.03) | (0.28) | (0.11) |
| Weighted Avg Shares | 28.9M | 66.41M | 103.11M | 187.18M | 207.87M |
| Weighted Avg Shares (Diluted) | 28.9M | 66.41M | 103.11M | 187.18M | 207.87M |
Esperion Therapeutics, Inc.
NASDAQ:ESPR
Intrinsic Alpha fair value
Locked
Current Price
$3.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.